Meeting Archives
Chemotherapy Foundation Symposium XXII
November 10-13, 2004
Marriott Marquis Hotel , New York , NY
Innovative Cancer Therapy for Tomorrow
Brain Tumors | Breast
Cancer | GI Cancers
Gynecological Cancers | Head
and Neck Cancer
Hematologic Malignancies | Lung
Cancer | Prostate
Cancer
Renal Cell Cancer | Sarcoma | Diverse
Therapies
New Agents and Strategies for the Oncology Team
BRAIN TUMORSModerators: Edward Ambinder, M.D., Silvia Formenti, M.D. |
|
| TEMOZOLOMIDE AND IRINOTECAN IN RECURRENT MALIGNANT
ASTROCYTOMA Michael Gruber, M.D. |
View Presentation |
| CLINICAL TRIAL RESULTS OF RSR 13 (EFAPROXIRAL) IN THERAPY
OF BRAIN METASTASES John Suh, M.D. |
View Presentation |
BREAST CANCERModerators: Larry Norton, M.D., George Raptis, M.D. |
|
| FASLODEX AND ARIMIDEX: 11/11/04 Anthony Howell, M.D. |
View Presentation |
| ROLE OF LETROZOLE IN ADJUVANT THERAPY William J. Gradishar, M.D. |
View Presentation |
| TAMOXIFEN AND EXEMESTANE IN THE METASTATIC AND ADJUVANT
SETTINGS: TRIAL RESULTS Stephen E. Jones, M.D. |
View Presentation |
| GEMCITABINE PLUS PACLITAXEL IN BREAST CANCER Denise Yardley, M.D. |
View Presentation |
| REMISSION RATE ADVANTAGE WITH NEOADJUVANT TRASTUZUMAB, PACLITAXEL
AND EPIRUBICIN-CONTAINING CHEMOTHERAPY Aman U. Buzdar, M.D. |
View Presentation |
| ORAL CHEMOTHERAPY FOR METASTATIC BREAST CANCER Julie R. Gralow, M.D. |
View Presentation |
| ABRAXANE IN METASTATIC BREAST CANCER Joanne C. Blum, M.D., Ph.D. |
View Presentation |
| ONCOTYPE DIAGNOSTIC ASSAY ON BREAST CANCER RECURRENCE Norman Wolmark, M.D. |
View Presentation |
| FEBRILE NEUTROPENIA IN DOCETAXEL-TREATED BREAST CANCER:
EVALUATING PEGFILGRASTIM Charles Vogel, M.D. |
View Presentation |
| eTAG ASSAY EFFICACY IN SELECTION OF PATIENTS FOR RECEPTOR-TARGETED
THERAPY Sharat Singh, Ph.D. |
View Presentation |
| CIRCULATING TUMOR CELLS IN METASTATIC BREAST CANCER Daniel F. Hayes, M.D. |
View Presentation |
| NEW STRATEGIES FOR ANTHRACYCLINE USE IN EARLY BREAST CANCER Edith Perez, M.D. |
View Presentation |
| HORMONAL TREATMENT OF BREAST CANCER: PROGRESS AND DIRECTIONS Maura N. Dickler, M.D. |
View Presentation |
GI CANCERSModerators: Howard S. Hochster, M.D., Steven Itzkowitz, M.D., Jonathan D. Schwartz, M.D. |
|
| OPTIONS WITH ORAL CHEMOTHERAPY IN CRC Edward Chu, M.D. |
View Presentation |
| OXALIPLATIN AS ADJUVANT THERAPY OF COLON CANCER Daniel Haller, M.D. |
View Presentation |
| RATIONAL TREATMENT OPTIONS FOR GIST: GLEEVEC, SU11248, RAD001
AND BEYOND George D. Demetri, M.D. |
View Presentation |
| ORAL ADJUVANT CHEMOTHERAPY IN COLORECTAL CANCER Christopher Twelves, M.D. |
View Presentation |
| IFOX (GEFITINIB , FU, OXALIPLATIN) IN COLORECTAL CANCER Branimir I. Sikic, M.D. |
View Presentation |
| OXALIPLATIN-BASED REGIMENS IN COMBINATION WITH BEVACIZUMAB
IN COLORECTAL CANCER Edward Chu, M.D |
View Presentation |
| OXALIPLATIN/FLUOROPYRIMIDE/AVASTIN IN METASTATIC COLORECTAL
CANCER Howard S. Hochster, M.D. |
View Presentation |
| PANITUMUMAB: A HUMAN ANTI-EGFR ANTIBODY IN COLORECTAL CANCER J. Randolph Hecht, M.D. |
View Presentation |
| QOL AND PHARMACOECONOMICS: ENDPOINTS IN ADJUVANT THERAPY
FOR COLON CANCER John L. Marshall, M.D. |
|
| ANGIOGENESIS IN COLORECTAL CANCER Heinz-Josef Lenz, M.D. |
View Presentation |
| BEVACIZUMAB PLUS GEMCITABINE FOR ADVANCED PANCREATIC CANCER Hedy Kindler, M.D. |
View Presentation |
| CHEMOTHERAPEUTIC DOUBLETS IN PANCREATIC CANCER Donald Richards, M.D. |
View Presentation |
| THALIDOMIDE/GEMCITABINE IN FIRST LINE PANCREATIC CANCER Willam Maples, M.D. |
View Presentation |
| NOVEL APPROACHES TO ESOPHAGOGASTRIC CANCER Peter C. Enzinger, M.D. |
View Presentation |
GYNECOLOGIC CANCERSModerator: Franco Muggia, M.D. |
|
| GEMCITABINE AND CARBOPLATIN IN 2ND LINE OVARIAN CANCER Robert F. Ozols, M.D., Ph.D. |
View Presentation |
| LONG TERM SURVIVAL ADVANTAGE: LIPOSOMAL DOXORUBICIN PHASE
II STUDY IN OVARIAN CANCER Alan N. Gordon, M.D. |
View Presentation |
| DOXIL: MAKING DOXORUBICIN WORK IN OVARIAN AND ENDOMETRIAL
CANCERS Franco M. Muggia, M.D. |
View Presentation |
| WEEKLY SCHEDULES IN OVARIAN CANCER Deborah Armstrong, M.D. |
View Presentation |
| TREATMENT AND PROTEOMIC MONITORING OF GEFITINIB IN ADVANCED
OVARIAN CANCER Elise Kohn, M.D. |
View Presentation |
| UPDATE ON CERVICAL CANCER THERAPY Harry J. Long, M.D. |
View Presentation |
HEAD AND NECK CANCERModerator: Edward Ambinder, M.D. |
|
| REDUCING CHEMORADIOTHERAPY-RELATED SIDE EFFECTS IN HEAD
AND NECK CANCER Marshall R. Posner, M.D. |
View Presentation |
| UPDATE ON DOCETAXEL IN HEAD AND NECK CANCER Marshall R. Posner, M.D. |
View Presentation |
| GEFITINIB IN HEAD AND NECK CANCER Ezra E. W. Cohen, M.D |
View Presentation |
HEMATOLOGIC MALIGNANCIESModerators: Janet Cutter, M.D., Janice Gabrilove, M.D., Jonathan Licht, M.D. |
|
| ERYTHROPOIETIC AGENTS: CLINICAL CONSIDERATIONS Charles Bennett, M.D., Ph.D., George Demetri, M.D. Janice L. Gabrilove, M.D., David Henry, M.D., M.P.H. |
|
| TARGETING THE UBIQUITIN-PROTEASOME PATHWAY IN HEMATOLOGIC
MALIGNANCIES Owen A. O’Connor, M.D. |
View Presentation |
| DENILEUKIN DIFTITOX AS NOVEL THERAPY FOR HEMATOLOGIC MALIGNANCIES Nam Dang, M.D., Ph.D. |
View Presentation |
| PIXANTRONE: A NEW AND ACTIVE DRUG IN LYMPHOMA Fernando Cabanillas, M.D. |
View Presentation |
| ZEVALIN IN DIFFUSE LARGE B-CELL LYMPHOMA Robin M. Joyce, M.D. |
View Presentation |
| R-CHOP FOLLOWED BY ZEVALIN IN FOLLICULAR NHL John D. Hainsworth, M.D. |
View Presentation |
| TREATMENT OF MDS WITH HYPOMETHYLATING AGENTS Stephen D. Nimer, M.D. |
View Presentation |
| AZACYTADINE: A NEWLY APPROVED AGENT IN MYELODYSPLASTIC SYNDROMES Richard M. Stone, M.D. |
View Presentation |
| BORTEZOMIB: NOVEL APPROACHES IN MULTIPLE MYELOMA Sundar Jagannath, M.D. |
View Presentation |
| TRISENOX REGIMEN IN MULTIPLE MYELOMA James R. Berenson, M.D. |
View Presentation |
| ROLE OF ALEMTUZUMAB AND RITUXIMAB IN CLL Kanti R. Rai, M.D. |
View Presentation |
| EXPERIENCE WITH DECITABINE IN CML AND MDS Hagop Kantarjian, M.D. |
View Presentation |
| CHROMATIN REMODELING AND HISTONE DEACETYLASE INHIBITORS
IN AML Guido Marcucci, M.D. |
View Presentation |
| CLOFARABINE PLUS ARA C COMBINATIONS IN AML Stefan Faderl, M.D. |
View Presentation |
| CAN WE CURE APL WITHOUT CYTOTOXIC CHEMOTHERAPY? Samuel Waxman, M.D. |
View Presentation |
| EFFICACY OF IMATINIB MESYLATE IN POLYCYTHEMIA VERA Richard T. Silver, M.D. |
View Presentation |
| LENALIDOMIDE (REVLIMID) FOR ANEMIA IN MYELODYSPLASTIC SYNDROMES Alan List, M.D. |
View Presentation |
| EVALUATING OPTIONS IN CHEMOTHERAPY-INDUCED ANEMIA Roger Waltzman, M.D. |
View Presentation |
| NEUTROPENIA IN 1ST CYCLE OF CHEMOTHERAPY: IMPACT OF PEG-FILGRASTIM Janice L. Gabrilove, M.D. |
View Presentation |
LUNG CANCERModerator: Philippe Chahinian, M.D. |
|
| IRINOTECAN/CISPLATINUM VS. ETOPOSIDE/CISPLATINUM IN SCLC Alan B. Sandler, M.D. |
View Presentation |
| PEMETREXED PLUS CARBOPLATIN OR OXALIPLATIN IN NSCLC Gorgio Scagliotti, M.D. |
View Presentation |
| EPOTHILONES: CLINICAL DEVELOPMENTS Edward S. Kim, M.D. |
View Presentation |
| OVERVIEW OF NEOADJUVANT AND ADJUVANT THERAPY FOR NSCLC Chandra P. Belani, M.D. |
View Presentation |
| CETUXIMAB IN CHEMORADIATION IN LOCALLY ADVANCED NSCLC Corey Langer, M.D. |
View Presentation |
| AVASTIN AND TARCEVA IN NSCLC Roy Herbst, M.D., Ph.D. |
View Presentation |
| UPDATE ON EGFR INHIBITORS IN NSCLC Roy Herbst, M.D., Ph.D. |
View Presentation |
| INHIBITION OF erbB PATHWAYS IN LUNG CANCER Afshin Dowlati, M.D. |
View Presentation |
| CYTOTOXIC THERAPY IN PS 2 ADVANCED NSCLC Cory Langer, M.D. |
View Presentation |
| BCI-2 ANTISENSE: NEW DEVELOPMENTS IN LUNG CANCER Roy S. Herbst, M.D., Ph.D |
View Presentation |
PROSTATE CANCERModerator: Anna Ferrari, M.D. |
|
| THERAPEUTIC OPTIONS IN ADVANCED PROSTATE CANCER Daniel Petrylak, M.D. |
View Presentation |
| ADJUVANT THERAPY IN HORMONE REFRACTORY PROSTATE CANCER Mario Eisenberger, M.D. |
View Presentation |
| ENDOTHELIN RECEPTOR ANTAGONISTS IN PROSTATE CANCER Michael A. Carducci, M.D. |
View Presentation |
| SOMETHING OLD; SOMETHING NEW: CHEMOIMMUNOTHERAPY
IN PROSTATE CANCER Jack Goldberg, M.D. |
View Presentation |
| PSMA: A TARGET IN FLUX FOR PROSTATE CANCER VACCINES Susan F. Slovin, M.D., Ph.D. |
View Presentation |
| PROVENGE: A NOVEL IMMUNOTHERAPY FOR PROSTATE CANCER Anna C. Ferrari, M.D. |
View Presentation |
RENAL CELL CANCER |
|
| ONCOPHAGE: AN AUTOLOGOUS HEAT SHOCK PROTEIN VACCINE Ronald M. Bukowski, M.D. |
View Presentation |
| REVLIMID (LENALIDOMIDE) IN RENAL CELL CANCER Robert J. Amato, M.D. |
View Presentation |
| SUGEN11248: A MULTITARGETED TYROSINE KINASE INHIBITOR IN
METASTATIC KIDNEY CANCER Robert J. Motzer, M.D. |
View Presentation |
DIVERSE THERAPIESModerators: Edward P. Ambinder, M.D., Silvia Formenti, M.D. |
|
| BAY 43-9006: A NOVEL RAF AND VEGF INHIBITOR WITH CARBOPLATIN
AND PACLITAXEL IN METASTATIC MELANOMA Keith T. Flaherty, M.D. |
View Presentation |
| YONDELIS – A NEW AGENT FOR THE TREATMENT OF SARCOMA Brian L. Samuels, M.D. |
View Presentation |
| CLINICAL UPDATE ON THE NOVEL mTOR-INHIBITOR RAD001 Howard A. Burris, III, M.D. |
View Presentation |
| UPDATE ON CLINICAL TRIALS WITH XYOTAX (CT-2103) Howard A. Burris, III, M.D. |
View Presentation |
| UPDATE ON RUBITECAN IN SOLID TUMORS Emiliano Calvo, M.D. |
View Presentation |
| BIOMARKERS AND GENETIC MUTATIONS Roy Herbst, M.D., Ph.D. |
View Presentation |
| MUC-1 CANCER VACCINES: ARE WE THERE YET? Charles A. Butts, M.D. |
View Presentation |
| ANTIANGIOGENIC THERAPY WITH VEGF OR VEGF RECEPTOR TARGETING
AGENTS Robert S. Kerbel, Ph.D. |
View Presentation |
| MOTEXAFIN GADOLINIUM: TUMOR SELECTIVE ANTICANCER AGENT WITH
NOVEL MECHANISM OF ACTION Leo I. Gordon, M.D. |
View Presentation |
| PREVENTION TARGETS IN p16INK4a METHYLATED EPITHELIAL CELLS Mona Gauthier, M.D. |
View Presentation |
| CANCER TREATMENT-INDUCED BONE LOSS: EMERGING PROBLEM IN
BREAST AND PROSTATE CANCER Allan Lipton, M.D. |
View Presentation |
| EGFR TESTING AND INTERPRETATION Meera Hameed, M.D. |
View Presentation |
| EGFR EXPRESSION RASH: ASSESSMENT, GRADING, TREATMENT Madeleine Duvic, M.D. |
View Presentation |
| LOW MOLECULAR WEIGHT HEPARINS IN THE MANAGEMENT OF MALIGNANCY-ASSOCIATED
THROMBOSIS Jawed Fareed, Ph.D. |
View Presentation |
NEW AGENTS AND STRATEGIES FOR THE ONCOLOGY TEAM CHEMOTHERAPY ... AND BEYOND |
|
| UTILIZING RADIOIMMUNOTHERAPY: CONSIDERATIONS FOR THE ONCOLOGY
TEAM Jennifer Fiore, R.N., M.A., A.N.P-C, O.C.N. |
View Presentation |
| CASE STUDIES CONTROVERSIES IN SUPPORTIVE CARE EASING THE
CHEMOTHERAPY EXPERIENCE: SUPPORTIVE CARE OPTIONS Maureen Major, R.N., M.S. |
View Presentation |
| PAIN MANAGEMENT: STILL AN ISSUE? Larry Driver, M.D. |
View Presentation |
| IMPLEMENTING BEST PRACTICES AND APPROPRIATE USE GUIDELINES Dwight Kloth, Pharm.D., F.C.C.P., B.C.O.P. |
View Presentation |
| PROJECTING AND CONTROLLING COSTS: THE M. D. ANDERSON EXPERIENCE Rebecca Arbuckle, M.S., R.Ph. |
View Presentation |
| HOW INFORMATION TECHNOLOGY SERVES THE CANCER CARE TEAM Edward P. Ambinder, M.D. |
View Presentation |
| AVOIDING MEDICATION ERRORS Raymond Muller, M.S., R.Ph., F.A.S.H.P. |
View Presentation |
| EZRA
M. GREENSPAN, M.D. 1919-2004 TALKING ABOUT EZRA Recollections by Friends and Colleagues of His Trailblazing Achievements in the Control and Cure of Cancer |
|
